Last reviewed · How we verify
NCT05309629
Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer
Phase 2 trial testing QL1706 in Extensive-stage Small-cell Lung Cancer in 40 participants. Completed in 13 December 2024.
1 February 2023
Quick facts
| Lead sponsor | Qilu Pharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 18 April 2022 |
| Primary completion | 1 February 2023 |
| Estimated completion | 13 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- QL1706 — full drug profile →
- Carboplatin (Carboplatin) — full drug profile →
- Etoposide (etoposide) — full drug profile →
Conditions studied
- Extensive-stage Small-cell Lung Cancer — all drugs for Extensive-stage Small-cell Lung Cancer →
Sponsor
Qilu Pharmaceutical Co., Ltd. — full company profile →
Who can join
Adults 18 to 75, any sex, with Extensive-stage Small-cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open label, phase 2 clinical study to evaluate the safety, tolerability, efficacy, pharmacokinetic (PK) profile, and immunogenicity of QL1706 plus carboplatin and etoposide as first-line therapy in patients with extensive-stage small cell lung cancer.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling.
Li T, Niu M, Zhou J, Wu K, et al · · 2024 · cited 31× · PMID 38475778 · DOI 10.1186/s12964-024-01562-5 -
Immunotherapy for extensive-stage small-cell lung cancer: current landscape and future perspectives.
Zhang S, Cheng Y. · · 2023 · cited 26× · PMID 37188176 · DOI 10.3389/fonc.2023.1142081 -
The Role of Immune Checkpoint Inhibitors in Cancer Therapy: Mechanism and Therapeutic Advances.
Chen H, Yang H, Guo L, Sun Q. · · 2025 · cited 1× · PMID 41059489 · DOI 10.1002/mco2.70412 -
Reframing small cell lung cancer: therapeutic lessons from hematologic malignancies.
Parmar K, Surolia I, Thomas A. · · 2026 · PMID 42147254 · DOI 10.3389/fonc.2026.1821271
Verify or expand the search:
- PubMed search for NCT05309629
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of QL1706
Trials testing the same drug.
- NCT07530549 — A Phase II Single-arm Clinical Study in the Treatment of Locally Advanced Esophageal Cancer After Failed Neoadjuvant Che · Phase 2 · not yet recruiting
- NCT07413601 — Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinu · Phase 2 · not yet recruiting
- NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting
- NCT06787183 — SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases · Phase 2 · recruiting
- NCT07172217 — The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC · Phase 2 · not yet recruiting
Other recruiting trials for Extensive-stage Small-cell Lung Cancer
Currently open trials in the same condition.
- NCT07244016 — Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment of ES-SCLC · recruiting
- NCT05588388 — Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell · Phase 2 · recruiting
- NCT06536868 — Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC · Phase 2 · recruiting
- NCT06217757 — Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC · Phase 1, PHASE2 · recruiting
- NCT06008353 — A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Un · active not recruiting
Other Qilu Pharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT07511647 — A Phase 3 Clinical Study of QL2106 Injection · Phase 3 · not yet recruiting
- NCT07467629 — QLS5212 for Participants With Advanced Solid Tumors · Phase 1 · not yet recruiting
- NCT07455006 — Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients · Phase 3 · not yet recruiting
- NCT07463573 — QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma · Phase 3 · not yet recruiting
- NCT07444086 — QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dyslipidemia · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05309629 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Qilu Pharmaceutical Co., Ltd.
- Last refreshed: 17 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05309629.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing